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Abstract
Background: JX594 is an oncolytic poxvirus derived from Wyeth strain vaccinia virus. We reported the presentation
of cutaneous and mucosal pustules containing laboratory-confirmed JX594 in a patient following injection of JX594.
Case presentation: A 36-year-old man was diagnosed hepatitis B virus-associated hepatocellular carcinoma on
September 19, 2011. Despite treatment with entecavir, radiofrequency ablation and transarterial chemoembolization
for recurrent local tumors, the tumors recurred in both lobes and lung metastases were detected by computed
tomography on September 12, 2012. The patient was treated with JX594 (Pexa-vec®) via intravenous injection on
December 19, 2012. No apparent adverse effects were observed following intravenous injection other than a single
fever episode. However, pustular lesions were detected on both sides of the tongue dorsum and on the proximal
interphalangeal joint of the right middle finger on December 25, 1012. Biopsy samples analyzed by PCR identified
the presence of the JX-594-specific hGM-CSF transgene and the disrupted viral thymidine kinase gene. Following
aspiration of the lesion a scab formed that resolved within 14 days without necessitating additional treatment.
Conclusion: Our case completely recovered and did not develop systemic or recurrent disease, the presentation of
a few pustules may not necessarily require that treatment with JX594 be interrupted for patients with advanced
hepatocellular carcinoma.
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Background
JX594 is an oncolytic poxvirus derived from the Wyeth
strain vaccinia virus [1]. Various modifications to JX594,
including the interruption of thymidine kinase, depend-
ency on epidermal growth factor receptor-ras pathway,
and resistance to interferon allow it to selectively repli-
cate within tumor cells [2]. Lysis of vaccinia virus-
infected tumor cells results as a consequence of viral
replication combined with tumor specific immunity that
is enhanced by JX594-derived granulocyte macrophage-
colony stimulating factor (GM-CSF). Injection of JX594
into melanoma patients or patients presenting with
advanced hepatic cancer either at the tumor site or sys-
temically can result in tumor regression [3, 4]. Adverse
effects reported following JX594 administration were
relatively mild (i.e., flu-like symptoms) [4] and JX594
dissemination to distant sites other than the target
tumor have been rarely reported. The present case re-
port describes a patient presenting with advanced
hepatocellular carcinoma that was treated with an
intravenous injection of JX594 prior to developing distant
skin and mucosal lesions containing laboratory-confirmed
JX594 virus.
Case presentation
The diagnosis of hepatitis B virus (HBV)-associated
hepatocellular carcinoma was confirmed by pathology
on a 36-year old male patient on September 19, 2011.
Despite treatment with entecavir, radiofrequency ablation
(September 29, 2011 and May 10, 2012), and transarterial
chemoembolization (July 30, 2012) for recurrent local
tumors, the tumors recurred in both lobes and lung
metastases were detected by computed tomography
on September 12, 2012.
Therefore, the patient was treated with an initial
dose (109 plaque forming unit [pfu]) of JX594 (Pexa-vec®)
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via intravenous injection on December 19, 2012
(ClinicalTrials.gov Identifier: NCT01387555). No apparent
adverse effects were observed following intravenous injec-
tion other than a single fever episode. However, on
December 25, 2012 pustular lesions were detected on the
proximal interphalangeal joint of the right middle finger
(Fig. 1a) and on both sides of the tongue dorsum (Fig. 1b).
Physical examination did not reveal any additional skin or
mucosal lesions. The patient’s contact history was unre-
markable. The patient’s white blood cell count on the day
the pustular lesions were identified were 7100 per cubic
millimeter (61.1 % neutrophils, 21.7 % lymphocytes)
and a hemoglobin concentration of 14.0 g/dl. Serology
was negative for measles virus, varicella zoster, EB-VCA,
rubella, and CMV. Pus aspirated from the pustules on
December 28 was JX594 positive. The discharge was
diluted and filtered using 0.45-μm-pre-size filter, and
cocultured with MRC-5 (lung fibroblast cell line). The
cells were then maintained in the minimal essential
medium (Gibco, life technologies, USA), supplemented
with 2 % fetal bovine serum and 1 % penicillin-
streptomycin-gentamycin at 37 °C with 5 % CO2. The
cytopathic effect, such as discohesive arrangement, cell
rounding and shrinkage, and necrosis with vesicles and
cell debris, was apparent (Fig. 1c). Biopsy samples
analyzed by PCR identified the presence of the JX-
594-specific hGM-CSF transgene (Primer pair 1) and
the disrupted viral thymidine kinase (TK) gene (Primer
pair 2, accession no. AF163844). The sequences amplified
were 99 % similar to the hGM-CSF (accession no.
M10663) and beta-galactosidase (accession no. U54829)
sequences available on the NCBI database. Following
aspiration of the lesion a scab formed that resolved
within 14 days without necessitating additional treatment.
The patient received intra-tumor injection on December
26, 2012 but there was no further skin or mucosal lesions
detected on follow-up.
Conclusions
Vaccination with vaccinia virus was used successfully as
part of the smallpox eradication program with low
adverse effects rates. Major complications such as gener-
alized vaccinia were approximately 86.7–122.2 per mil-
lion vaccinations [5]. Theoretically, this suggested that
vaccinia virus engineered to replicate exclusively within
tumor cells would also be associated with low complica-
tion rates. During a phase 1 trial, 1 case that received a
high intratumor injection dose of JX594 (109 PFU)
developed multiple pustules 4 days latter [4], but this
manifestation was not observed in other patients (during
other clinical trials) injected with lower doses [3, 6, 7].
However, follow-up experiments designed to identify
Fig. 1 a The patient developed a pustular lesion on the proximal interphalangeal joint of the right middle fingerfollowing intravenous injection
with JX594. b Other pustular lesions were noted on the both sides of the tongue dorsum. c The cytopathic effect was observed by co-culturing
the virus with MRC-5 cells. Asterisk: normal MRC-5 cells structure; Thin arrow: discohesive structure; Bold arrow: rounded cell; Arrowhead: necrotic
debris and vesicles. d PCR designed to amplify the JX-594-specific hGM-CSF transgene (Primer pair 1) and the disrupted viral thymidine kinase
gene (Primer pair 2) was positive. M, marker; NC, negative control
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vaccina virus in the pustules were not performed in the
suspected case [4]. In contrast, live virus was identified
in the aspirates of the present case study and PCR analysis
identified the presence of a disrupted thymidine kinase
gene (associated with JX594) suggesting that JX594 repli-
cated within the epithelial cells of the patient’s oral cavity
and skin. These data suggested that the lesions discovered
on December 25, 2012 were caused by the systemic
spread of JX594 following intravenous injection on
December 19, 2012.
Following small pox vaccination, papules typically
present 4–5 days later and become pustular within 7–10
days. The pustules identified in our case (and on the
previously described case [4]) appeared following the
first dose of JX594 but did not recur. It is not known
whether the neutralizing antibody which developed in
almost all cases receiving JX594 may have a role in pre-
venting subsequent pustule development considering the
replication and good treatment efficacy of JX594 in the
presence of high titer of neutralizing antibody in previ-
ous reports [4, 7]. Since our case and the previous
suspected case [4] completely recovered and did not de-
velop systemic or recurrent disease, the presentation of a
few pustules may not necessarily require that treatment
with JX594 be interrupted for patients with advanced
hepatocellular carcinoma.
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